Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout ... and RA Capital among its notable investors. Its initial product candidate, IDRX-42, targets gastrointestinal stromal tumor ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

While for some individuals it has increased trust in vaccination and the pharma industry ... during which Piyali Mukherjee, GSK’s head of global medical affairs, vaccines, outlined why adult ...

GSK's severe ... at a future medical congress, but is strong enough to warrant discussions with regulators about extending the indications for Nucala, according to the pharma group.

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK plc (LSE/NYSE ... for depemokimab have been accepted for review by the China National Medical (TASE:PMCN) Products Administration and submitted to the Japanese Ministry of Health, Labour ...

Abbott India posts Q2 profit rise on strong demand, price hikes November 7, 2024 India's GlaxoSmithKline ... $897 million to manufacture products for the U.S. pharmaceutical giant.

GlaxoSmithKline Pharmaceuticals Ltd on Friday reported a 37.87 per cent rise in consolidated net profit at Rs 182.33 crore in the first quarter ended June 30, 2024. The company had posted a ...